BLASUBCUTANEOUSINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
IRA Negotiated
PYZCHIVA (ustekinumab-ttwe) by Samsung Bioepis is interleukin-12 antagonists [moa]. Approved for psoriasis, crohn's disease, ulcerative colitis and 1 more indications. First approved in 2024.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYZCHIVA (ustekinumab-ttwe) is a monoclonal antibody antagonist of interleukin-12 (IL-12) approved in June 2024 as a biosimilar to the reference product. It is indicated across a broad spectrum of immune-mediated diseases including psoriasis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), psoriatic arthritis, ankylosing spondylitis, and emerging indications in Type 1 diabetes, lupus, and other autoimmune conditions. The drug works by blocking IL-12 signaling, reducing pathogenic immune responses in multiple organ systems.
Growth
Early-stage biosimilar in growth phase with significant IRA price negotiation; initial team build will focus on market penetration and payer infrastructure.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications (4)
Worked on PYZCHIVA at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.